Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer

Joon Oh Park, Hyuncheol Chung, Jae Yong Cho, SunYoung Rha, Nae Choon You, Joo Hang Kim, Sung Hoon Noh, Choong Bai Kim, Jin Sik Min, Byung Soo Kim, Jae Kyung Roh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

About one-third of patients with gastric cancer are unresectable at the time of diagnosis. Their median survival is < 6 months, with a grave prognosis. The purpose of this study was to assess the efficacy of a modified FAM (mFAM) regimen in advanced gastric cancer. We retrospectively reviewed the clinical records of 409 advanced gastric cancer patients who had not received curative surgery. Among 409 patients, 202 patients were treated with an mFAM regimen (infusional 5-FU + doxorubocin + mitomycin-C), and 207 patients received no chemotherapy (control group). No differences were found in clinical parameters between the two groups. The 1-year survival rates were 34.1% for the mFAM-treated group and 22.5% for the control group (p = 0.0135). In subset analysis, a higher 1-year survival rate was demonstrated in patients with mFAM and palliative surgery. Of the 154 evaluable patients in the mFAM-treated group, the response rate was 17.5%. In these patients, median response duration was 30 weeks, and progression-free survival was 23 weeks. Overall toxicity of mFAM regimen was relatively tolerable and reversible. In conclusion, FAM combination chemotherapy, which has been used as a standard therapy, prolonged survival after modification of the administration schedule and combination with palliative surgery. A prospective randomized study is warranted to confirm this conclusion from our retrospective study.

Original languageEnglish
Pages (from-to)484-489
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume20
Issue number5
DOIs
Publication statusPublished - 1997 Oct 1

Fingerprint

Mitomycin
Combination Drug Therapy
Palliative Care
Fluorouracil
Doxorubicin
Stomach Neoplasms
Therapeutics
Survival Rate
Control Groups
Survival
Disease-Free Survival
Appointments and Schedules
Retrospective Studies
Prospective Studies
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Park, Joon Oh ; Chung, Hyuncheol ; Cho, Jae Yong ; Rha, SunYoung ; You, Nae Choon ; Kim, Joo Hang ; Noh, Sung Hoon ; Kim, Choong Bai ; Min, Jin Sik ; Kim, Byung Soo ; Roh, Jae Kyung. / Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1997 ; Vol. 20, No. 5. pp. 484-489.
@article{3309b63e8f7a44439738af414dd5b603,
title = "Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer",
abstract = "About one-third of patients with gastric cancer are unresectable at the time of diagnosis. Their median survival is < 6 months, with a grave prognosis. The purpose of this study was to assess the efficacy of a modified FAM (mFAM) regimen in advanced gastric cancer. We retrospectively reviewed the clinical records of 409 advanced gastric cancer patients who had not received curative surgery. Among 409 patients, 202 patients were treated with an mFAM regimen (infusional 5-FU + doxorubocin + mitomycin-C), and 207 patients received no chemotherapy (control group). No differences were found in clinical parameters between the two groups. The 1-year survival rates were 34.1{\%} for the mFAM-treated group and 22.5{\%} for the control group (p = 0.0135). In subset analysis, a higher 1-year survival rate was demonstrated in patients with mFAM and palliative surgery. Of the 154 evaluable patients in the mFAM-treated group, the response rate was 17.5{\%}. In these patients, median response duration was 30 weeks, and progression-free survival was 23 weeks. Overall toxicity of mFAM regimen was relatively tolerable and reversible. In conclusion, FAM combination chemotherapy, which has been used as a standard therapy, prolonged survival after modification of the administration schedule and combination with palliative surgery. A prospective randomized study is warranted to confirm this conclusion from our retrospective study.",
author = "Park, {Joon Oh} and Hyuncheol Chung and Cho, {Jae Yong} and SunYoung Rha and You, {Nae Choon} and Kim, {Joo Hang} and Noh, {Sung Hoon} and Kim, {Choong Bai} and Min, {Jin Sik} and Kim, {Byung Soo} and Roh, {Jae Kyung}",
year = "1997",
month = "10",
day = "1",
doi = "10.1097/00000421-199710000-00010",
language = "English",
volume = "20",
pages = "484--489",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. / Park, Joon Oh; Chung, Hyuncheol; Cho, Jae Yong; Rha, SunYoung; You, Nae Choon; Kim, Joo Hang; Noh, Sung Hoon; Kim, Choong Bai; Min, Jin Sik; Kim, Byung Soo; Roh, Jae Kyung.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 20, No. 5, 01.10.1997, p. 484-489.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer

AU - Park, Joon Oh

AU - Chung, Hyuncheol

AU - Cho, Jae Yong

AU - Rha, SunYoung

AU - You, Nae Choon

AU - Kim, Joo Hang

AU - Noh, Sung Hoon

AU - Kim, Choong Bai

AU - Min, Jin Sik

AU - Kim, Byung Soo

AU - Roh, Jae Kyung

PY - 1997/10/1

Y1 - 1997/10/1

N2 - About one-third of patients with gastric cancer are unresectable at the time of diagnosis. Their median survival is < 6 months, with a grave prognosis. The purpose of this study was to assess the efficacy of a modified FAM (mFAM) regimen in advanced gastric cancer. We retrospectively reviewed the clinical records of 409 advanced gastric cancer patients who had not received curative surgery. Among 409 patients, 202 patients were treated with an mFAM regimen (infusional 5-FU + doxorubocin + mitomycin-C), and 207 patients received no chemotherapy (control group). No differences were found in clinical parameters between the two groups. The 1-year survival rates were 34.1% for the mFAM-treated group and 22.5% for the control group (p = 0.0135). In subset analysis, a higher 1-year survival rate was demonstrated in patients with mFAM and palliative surgery. Of the 154 evaluable patients in the mFAM-treated group, the response rate was 17.5%. In these patients, median response duration was 30 weeks, and progression-free survival was 23 weeks. Overall toxicity of mFAM regimen was relatively tolerable and reversible. In conclusion, FAM combination chemotherapy, which has been used as a standard therapy, prolonged survival after modification of the administration schedule and combination with palliative surgery. A prospective randomized study is warranted to confirm this conclusion from our retrospective study.

AB - About one-third of patients with gastric cancer are unresectable at the time of diagnosis. Their median survival is < 6 months, with a grave prognosis. The purpose of this study was to assess the efficacy of a modified FAM (mFAM) regimen in advanced gastric cancer. We retrospectively reviewed the clinical records of 409 advanced gastric cancer patients who had not received curative surgery. Among 409 patients, 202 patients were treated with an mFAM regimen (infusional 5-FU + doxorubocin + mitomycin-C), and 207 patients received no chemotherapy (control group). No differences were found in clinical parameters between the two groups. The 1-year survival rates were 34.1% for the mFAM-treated group and 22.5% for the control group (p = 0.0135). In subset analysis, a higher 1-year survival rate was demonstrated in patients with mFAM and palliative surgery. Of the 154 evaluable patients in the mFAM-treated group, the response rate was 17.5%. In these patients, median response duration was 30 weeks, and progression-free survival was 23 weeks. Overall toxicity of mFAM regimen was relatively tolerable and reversible. In conclusion, FAM combination chemotherapy, which has been used as a standard therapy, prolonged survival after modification of the administration schedule and combination with palliative surgery. A prospective randomized study is warranted to confirm this conclusion from our retrospective study.

UR - http://www.scopus.com/inward/record.url?scp=0343923729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343923729&partnerID=8YFLogxK

U2 - 10.1097/00000421-199710000-00010

DO - 10.1097/00000421-199710000-00010

M3 - Article

C2 - 9345333

AN - SCOPUS:0343923729

VL - 20

SP - 484

EP - 489

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -